BioPharma

Joseph Wolk, Johnson & Johnson chief financial officer, discusses the company's fourth-quarter results, drug portfolio plans and industry pricing pressure.

Suit didn’t show McKesson participated in price fixing, judge says.

A generic version of Copaxone, one of the most popular drugs to treat multiple sclerosis, didn't do much to lower costs for patients.

Well here’s what happened when Germany ignored those warnings.

About 3,400 pharmacies in Lebanon are suffering from the drop in prices of pharmaceutical drugs, facing the risk of shutting down in the years to come if they can't secure enough revenues.

Computers are sifting through an endless archive of biological data and quickly finding patterns that it would take a human a lifetime to discover.

Valrox would be first gene therapy approved in U.S. for inherited type of hemophilia.

Eli Lilly CEO David Ricks about its efforts to offer lower-priced insulin.

None, however, offered to cut the prices of their own drugs.

Third-to-market plans to aggressively challenge pricing of two of the world’s most expensive medicines.

Eli Lilly and Co plans to sell two versions of insulin products at half their current U.S. list prices.

From instalment-plans to subscriptions to more complex value-based contracts, pharma companies are tinkering with how they get paid.

GlaxoSmithKline CEO Emma Walmsley told "Mad Money" host Jim Cramer the British drugmaker has received "positive data" for cancer and HIV drugs.

Bristol-Myers Squibb CEO Dr. Giovanni Caforio sits down with CNBC's Jim Cramer at the J.P. Morgan Healthcare Conference in San Francisco.

Sam Waksal, ImClone Systems founder, and CNBC's Meg Tirrell join "Closing Bell" in an exclusive interview from JPMorgan's Healthcare Conference.